Literature DB >> 24812413

MET as a target in papillary renal cell carcinoma.

André P Fay1, Sabina Signoretti2, Toni K Choueiri3.   

Abstract

The biology underlying papillary renal cell carcinoma (pRCC) is largely unknown, and no specific therapies have been developed for advanced disease. The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24812413     DOI： 10.1158/1078-0432.CCR-14-0690

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  4 in total

Review 1.  MET deregulation in breast cancer.

Authors:  Gabriele Minuti; Lorenza Landi
Journal:  Ann Transl Med       Date:  2015-08

2.  Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response.

Authors:  Xi Tian; Wen-Hao Xu; Fu-Jiang Xu; Hui Li; Aihetaimujiang Anwaier; Hong-Kai Wang; Fang-Ning Wan; Yu- Zhu; Da-Long Cao; Yi-Ping Zhu; Guo-Hai Shi; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

3.  Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.

Authors:  Xiaolu Yin; Tianwei Zhang; Xinying Su; Yan Ji; Peng Ye; Haihua Fu; Shuqiong Fan; Yanying Shen; Paul R Gavine; Yi Gu
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

Review 4.  Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.

Authors:  Paolo Grassi; Elena Verzoni; Raffaele Ratta; Alessia Mennitto; Filippo de Braud; Giuseppe Procopio
Journal:  Drug Des Devel Ther       Date:  2016-07-05       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.